{"id":"NCT04541043","sponsor":"Calliditas Therapeutics AB","briefTitle":"Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)","officialTitle":"An Open-Label Extension (OLE) Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients With IgA Nephropathy Who Have Completed Study Nef-301","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-11-17","primaryCompletion":"2024-02-26","completion":"2024-02-26","firstPosted":"2020-09-09","resultsPosted":"2025-01-03","lastUpdate":"2025-02-10"},"enrollment":119,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary IgA Nephropathy"],"interventions":[{"type":"DRUG","name":"Nefecon 16mg daily","otherNames":[]}],"arms":[{"label":"Active Nefecon treatment","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in patients with IgAN who have completed the Phase 3 Study Nef-301 and continue to be treated with a stable dose of RAS inhibitor therapy (ACEIs and/or ARBs). Patients who previously received Nefecon in Study Nef-301 will receive retreatment, whereas patients who previously received placebo in Study Nef-301 will be treatment naïve to Nefecon.","primaryOutcome":{"measure":"Ratio of Urine Protein to Creatine Ratio (UPCR) at 9 Months Compared to Baseline","timeFrame":"9 months","effectByArm":[{"arm":"Retreatment - Previously Treated With Nefecon in Nef-301 Study","deltaMin":0.67,"sd":null},{"arm":"Delayed Treatment - Previously Treated With Placebo in Nef-301 Study","deltaMin":0.69,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":18,"countries":["United States","Argentina","Australia","Belarus","Belgium","Canada","Czechia","Finland","France","Germany","Greece","Italy","Poland","South Korea","Spain","Sweden","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":45},"commonTop":["Corona virus infection","Hypertension","Weight increased","Oedema peripheral","Muscle spasms"]}}